146.30
-3.97(-2.64%)
Currency In USD
Previous Close | 150.27 |
Open | 150 |
Day High | 150.81 |
Day Low | 146.3 |
52-Week High | 207.84 |
52-Week Low | 122.8 |
Volume | 246,964 |
Average Volume | 374,930 |
Market Cap | 4.23B |
PE | 29.8 |
EPS | 4.91 |
Moving Average 50 Days | 143.29 |
Moving Average 200 Days | 160.15 |
Change | -3.97 |
If you invested $1000 in Krystal Biotech, Inc. (KRYS) since IPO date, it would be worth $13,750 as of August 18, 2025 at a share price of $146.3. Whereas If you bought $1000 worth of Krystal Biotech, Inc. (KRYS) shares 5 years ago, it would be worth $3,261.98 as of August 18, 2025 at a share price of $146.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
GlobeNewswire Inc.
Jul 29, 2025 11:00 AM GMT
PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, p
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire Inc.
Jul 25, 2025 1:00 PM GMT
VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family VYJUVEK is the first and only genetic medicine approved in Japan for the
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
GlobeNewswire Inc.
Jul 24, 2025 12:00 PM GMT
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly